Drug Trial News

RSS

Novartis Bexsero pivotal study data on meningococcal serogroup B presented at ESPID

New data from a pivotal study in more than 1,800 infants show that Novartis candidate vaccine Bexsero induces a robust immune response to meningococcal serogroup B when given alone or when co-administered with other routine vaccines.

15 Jun 2011

Reovirus with paclitaxel, carboplatin can treat metastatic non-small cell lung cancer

A type of virus known as the human reovirus possesses a remarkable trait: It can replicate inside and kill cancer cells that feature a common mutation, while leaving the body's normal cells alone.

15 Jun 2011

immatics initiates IMA901 Phase III trial in renal cell carcinoma

igoommatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced today that the first patients have been vaccinated in the IMPRINT study, a pivotal Phase III trial with IMA901, the company's lead cancer vaccine for the treatment of renal cell carcinoma.

15 Jun 2011

Meda presents new positive results from Dymista Phase-III trial on AR at EAACI 2011

Meda presents new positive results from a Phase-III clinical trial of Dymista at the annual meeting of the European Academy of Allergy and Clinical Immunology (EAACI) in Istanbul, Turkey.

15 Jun 2011

Sangart commences MP4OX Phase 2b study in acute traumatic injury

Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic tissues through targeted oxygen and other gas delivery, today announced the initiation of a Phase 2b study designed to evaluate the efficacy and safety of MP4OX treatment plus standard of care in severely injured trauma patients with lactic acidosis due to hemorrhagic shock.

15 Jun 2011

Bayer's submission of IND for BAY 94-9343 triggers $2M milestone payment to ImmunoGen

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that Bayer HealthCare Pharmaceuticals' submission of an Investigational New Drug (IND) application for the TAP compound, BAY 94-9343, triggers a $2 million milestone payment to ImmunoGen.

15 Jun 2011

Positive results from Neurelis NRL-01 Phase 1 trial against epilepsy

Neurelis, Inc. today announced the results of a randomized crossover study in healthy volunteers assessing diazepam pharmacokinetics and bioavailability after administration of their proprietary intranasal diazepam formulations and intravenous injection.

15 Jun 2011

CorMedix completes enrollment in CRMD001 Phase II trial for treatment of acute kidney injury

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announced it successfully completed patient enrollment in its phase II Contrast-Induced Acute Kidney Injury study with its oral drug candidate CRMD001.

14 Jun 2011

The Lancet publishes final 3-year data from landmark HORIZONS-AMI clinical trial

Data from the landmark HORIZONS-AMI clinical trial demonstrated that the administration of the anticoagulant medication bivalirudin enhanced survival compared to the use of heparin plus a glycoprotein (GP) IIb/IIIa inhibitor in heart attack patients undergoing angioplasty after 3 years. Use of a drug-eluting stent was also shown to be more effective than a bare-metal stent, with equivalent safety.

14 Jun 2011

TWi Biotech enrolls over 50% of patients for AC-201 Phase IIb trial against Type II Diabetes

TWi Biotechnology Inc. announced today that the company has enrolled over 50% of the total 240 patients for the Phase IIb clinical trial of AC-201 for the treatment of Type II Diabetes.

14 Jun 2011

New findings from Deplin clinical trial on major depressive disorder presented at NCDEU

New findings from a multi-center, randomized, placebo-controlled clinical study of Deplin 15mg added to commonly prescribed antidepressants known as selective serotonin reuptake inhibitors showed that all patients who achieved remission at 30 days using Deplin 15mg adjuvant therapy, and who chose to enter a 12 month maintenance phase, maintained their remission after a year of treatment.

14 Jun 2011

Orexo completes first OX27 pharmacokinetic trial against breakthrough pain in cancer

Orexo AB announces a successful outcome following completion of the first OX27 pharmacokinetic trial.

14 Jun 2011

GE Healthcare announces results of Optison heart ultrasound contrast agent presented at ASE

Today, GE Healthcare Medical Diagnostics announced results of a study that evaluated the cardiopulmonary safety of Optison- (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a diagnostic ultrasound contrast agent for use in improving suboptimal echocardiograms.

14 Jun 2011

FDA approves Cornell Dots for first-in-human clinical trial for treatment of cancer

The U.S. Food and Drug Administration (FDA) has approved the first clinical trial in humans of a new technology: Cornell Dots, brightly glowing nanoparticles that can light up cancer cells in PET-optical imaging.

14 Jun 2011

Cinryze data on hereditary angioedema presented at EAACI 2011

ViroPharma Incorporated today announced that data relating to Cinryze from nine accepted abstracts were presented as poster presentations at the 30th Congress of the European Academy of Allergy and Clinical Immunology (EAACI), June 11 through 15, in Istanbul, Turkey.

14 Jun 2011

Astellas, Ambit Biosciences announce interim results from AC220 Phase 2 trial against AML

Ambit Biosciences Corporation and Astellas Pharma Inc. announced today results from a planned interim analysis in an ongoing Phase 2 study evaluating AC220, a potent and selective FLT3 inhibitor.

14 Jun 2011

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that preliminary results from its ENABLE Phase 2 proof-of-concept trial demonstrated that bafetinib, the Company's Bcr-Abl, Lyn and Fyn kinase inhibitor, was clinically active in a group of patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL) who have failed several other treatments for their cancer.

13 Jun 2011

Study reveals positive impact of Soliris on long-term outcomes in PNH patients

Alexion Pharmaceuticals, Inc. today announced the presentation of research that provides further insight into the clinical consequences of paroxysmal nocturnal hemoglobinuria (PNH), and positive impact of Soliris® (eculizumab) therapy on long-term outcomes.

13 Jun 2011

CEL-SCI initiates Multikine Phase III clinical trial for head and neck cancer in Hungary

CEL-SCI Corporation announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, at the National Institute of Oncology in Budapest, Hungary. Enrollment is expected to start soon in this center. The study is already ongoing at twelve clinical sites in the United States, Canada, Poland and India.

13 Jun 2011

Trimeris, Synageva enter definitive merger agreement

Synageva BioPharma Corp., a privately held biopharmaceutical company developing therapeutic products for rare disorders, and Trimeris, Inc., announced today that they have entered into a definitive agreement under which Synageva will merge with Trimeris in an all-stock transaction.

13 Jun 2011

Drug Trial News

Novartis Bexsero pivotal study data on meningococcal serogroup B presented at ESPID

Reovirus with paclitaxel, carboplatin can treat metastatic non-small cell lung cancer

immatics initiates IMA901 Phase III trial in renal cell carcinoma

Meda presents new positive results from Dymista Phase-III trial on AR at EAACI 2011

Sangart commences MP4OX Phase 2b study in acute traumatic injury

Bayer's submission of IND for BAY 94-9343 triggers $2M milestone payment to ImmunoGen

Positive results from Neurelis NRL-01 Phase 1 trial against epilepsy

CorMedix completes enrollment in CRMD001 Phase II trial for treatment of acute kidney injury

The Lancet publishes final 3-year data from landmark HORIZONS-AMI clinical trial

TWi Biotech enrolls over 50% of patients for AC-201 Phase IIb trial against Type II Diabetes

New findings from Deplin clinical trial on major depressive disorder presented at NCDEU

Orexo completes first OX27 pharmacokinetic trial against breakthrough pain in cancer

GE Healthcare announces results of Optison heart ultrasound contrast agent presented at ASE

FDA approves Cornell Dots for first-in-human clinical trial for treatment of cancer

Cinryze data on hereditary angioedema presented at EAACI 2011

Astellas, Ambit Biosciences announce interim results from AC220 Phase 2 trial against AML

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

Study reveals positive impact of Soliris on long-term outcomes in PNH patients

CEL-SCI initiates Multikine Phase III clinical trial for head and neck cancer in Hungary

Trimeris, Synageva enter definitive merger agreement

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News